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Abstract
The emergence of pandemic A(H1N1) 2009 influenza showed the importance of rapid assessment of the degree of immunity in the
population, the rate of asymptomatic infection, the spread of infection in households, effects of control measures, and ability of candi-
date vaccines to produce a response in different age groups. A limitation lies in the available assay repertoire: reference standard meth-
ods for measuring antibodies to influenza virus are haemagglutination inhibition (HI) assays and virus neutralization tests. Both assays
are difficult to standardize and may be too specific to assess possible partial humoral immunity from previous exposures. Here, we
describe the use of antigen-microarrays to measure antibodies to HA1 antigens from seven recent and historical seasonal H1, H2 and
H3 influenza viruses, the A(H1N1) 2009 pandemic influenza virus, and three avian influenza viruses. We assessed antibody profiles in 18
adult patients infected with A(H1N1) 2009 influenza virus during the recent pandemic, and 21 children sampled before and after the
pandemic, against background reactivity observed in 122 persons sampled in 2008, a season dominated by seasonal A(H1N1) influenza
virus. We show that subtype-specific and variant-specific antibody responses can be measured, confirming serological responses mea-
sured by HI. Comparison of profiles from persons with similar HI response showed that the magnitude and broadness of response to
individual influenza subtype antigens differs greatly between individuals. Clinical and vaccination studies, but also exposure studies,
should take these findings into consideration, as they may indicate some level of humoral immunity not measured by HI assays.
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Background
The recent pandemic spread of a new influenza A(H1N1) virus
and the continued threat posed by widespread circulation of
highly pathogenic influenza A(H5N1) viruses shows the impor-
tance of influenza surveillance [1]. The worldwide network for
influenza surveillance of the World Health Organization relies
on a combination of clinical, epidemiological, virological and
immunological surveillance [2,3]. Isolates of dominant circulat-
ing strains, as well as unusual isolates, are characterized using
sera from ferrets immunized with different strains in haemag-
glutination inhibition assays (HI) and microneutralization assays
[3]. Viruses that escape HI or neutralization become a problem
upon further circulation, because the level of immunity in the
population is expected to be suboptimal [1,4,5].
The 2009 pandemic was triggered by a descendent from
the 1918 strain that had been introduced into pigs during
the Spanish flu pandemic, and from which the HA and NA
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continued to be present in circulating swine influenza
viruses without interruption [5–8]. Crucial determinants of
the potential impact of this new influenza pandemic had to
be determined through serosurveys, for instance the level
of immunity in the population, the rate of asymptomatic
infections, the spread of infection in households, the effect
of control measures on spread of infection, and the ability
of candidate vaccines to produce an effective response in
different age groups [9]. A factor influencing the response
to serological surveys is the requirement for significant
amounts of serum if reactivity against multiple antigens
needs to be tested. In population-based surveys of expo-
sure to these viruses, children typically are under-repre-
sented because of reluctance to carry out invasive sampling,
especially in the very young. A further limitation lies in the
available assay repertoire: reference standard methods for
measuring antibody to influenza are hemagglutination inhibi-
tion (HI) assays and virus neutralization tests (VNT)
[10,11].
HI titres have become the accepted correlate of protec-
tion, and form the basis for evaluation of vaccines, but
results of HI and VNT are sometimes discrepant, and het-
erologous protection from disease caused by influenza virus
strains has been described that was unrelated to levels of
HI or VN antibodies. Although this is thought to be mostly
related to cross-protective cytotoxic T-cell responses, anti-
bodies may also play a role [12,13]. The results of HI may
vary depending on the strain, and single amino acid substi-
tution may change the degree of glycosylation, the affinity
of binding of HA to the receptor, and subsequently the
level of antibody response [14]. Exposure of humans to ani-
mal influenza viruses does not consistently lead to detect-
able HI antibody titres despite virological proof of infection
[15–17]. Finally, HI assays require the use of animal red
blood cells, and are difficult to standardize, making compari-
son of results across studies difficult [18]. For all the rea-
sons listed, there is a need for novel methodologies that
enable simultaneous measurements of antibody responses
to a range of different viruses using minimal amounts of
serum. Methods based on recombinant HA antigens have
shown some promise, but specificity may be limited due to
broad cross-reactivity with antibodies induced by heterolo-
gous influenza viruses [19,20].
Here, we describe the profiling of antibody responses in
humans to a range of recent and historical seasonal influenza
viruses in a small volume of serum (10 lL). The HA1 was
chosen because it is the dominant target of protective anti-
body responses, and, unlike the complete HA, contains less
cross-reactive epitopes that might cause specificity problems
[8,21].
Materials and Methods
Sera
For validation experiments we used the following.
1. Anonymized serum samples from 122 persons ranging in
age from <1 to 95 years sampled during 2008. They had
been sent to our institute to test for antibodies to Borde-
tella pertussis, and thus there is a bias toward persons
with respiratory symptoms, but not influenza-like illness.
All serum samples had been stored at )20C prior to
testing.
2. Consecutive sera from 18 persons without a history of
seasonal influenza virus vaccination, who had been diag-
nosed with influenza by RT-PCR testing of a throat/nose
swab during the active case finding activities instituted in
the early phase of the pandemic. Persons testing positive
were asked if they were willing to participate in a
national cohort study. Blood was collected by venapunc-
ture, and samples were sent to RIVM the same day for
processing (t = 1). Follow-up sampling was carried out at
days 4–6 from the first moment of contact (t = 2),
between days 9 and 11 (t = 3), and, for consenting per-
sons, after 28–35 days (t = 4). Sera were stored at
)20C prior to testing and were tested for HI antibod-
ies using a WHO reference method (I. H. M. Friesema,
A. Meijer, A. B. van Gageldonk-lafeber, M. van der Lub-
ben, J. van Beek, G. A. Donker, J. M. Prins, M. D. de
Jong, S. Boskamp, L. D. Isken, M. P. G. Koopmans and
M. A. B. van der Sande, manuscript in preparation).
3. Paired plasma samples from 21 children, 9 years of age,
who had been sampled as part of an ongoing longitudinal
study of memory immunity to pertussis (IS-
RCTN64117538), in March 2009 just before the first pan-
demic wave and in March 2010, after the first pandemic
wave in the Netherlands. Written informed consent was
obtained from both parents/legal representatives.
The sampling of patients was approved by the Medical Ethical
Review board. The submission form for diagnostic specimens
specifies that anonymized samples may be used for assay vali-
dation studies and as reference material, unless the patient
specifically objects by ticking a box on the form. This
approach is allowed under Dutch law.
Preparation and analysis of microarrays
Commercially available HA1 proteins of H1, H2, H3, H5, H7
and H9 influenza A viruses produced in a human cell line
(human embryonic kidney 293 cells; HEK293-cells) to ensure
proper glycosylation [22] and purified by HIS-tag purification
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were used (Immune Technology, NewYork, NY, USA)
(Table 1). Recombinant HA1 proteins were spotted in two
drops of 333 pL in protein arraying buffer (Whatman, Maid-
stone, Kent, UK) containing protease inhibitor (BioVision,
Mountain View, CA, USA), using a non-contact Piezorray
spotter (PerkinElmer, Waltham, MA, USA) on 16-pad nitro-
cellulose coated slides (Oncyte avid, Grace bio-labs, Bend,
OR, USA) to avoid conformational changes. Starting concen-
trations were around 200 mg/L, but optimal reaction condi-
tions for each antigen were determined by checkerboard
titration. Antigens were spotted in triplicate on each array
(Fig. 1). A tray consists of four slides, comparable to a 96-well
plate with only eight lanes, thus functionally yielding 64 wells.
Within- and between-tray variation were monitored by test-
ing titration series of the international standard for antibody
to pandemic A(H1N1) 2009 influenza virus (IS; http://
www.nibsc.ac.uk/documents/ifu/09-194.pdf). After spotting,
slides were kept overnight in a drying chamber and stored at
room temperature in the dark until further use. Stability was
tested by retesting slides from the same batch after storage
for up to 3 weeks. A range of initial experiments were car-
ried out to optimize the spotting of arrays, using slides of dif-
ferent suppliers, blocking buffers, wash buffers and
conjugates, leading to the reagent choices described here.
Slides were treated with Blotto-blocking buffer to avoid
non-specific binding to the nitrocellulose surface (Thermo
Fisher Scientific Inc., Rockford, MA, USA) for 1 h at 37C in
a moist chamber. Slides were washed three times with pro-
tein array wash-buffer in between each step (Whatman Bred-
ford, USA). Serial two-fold dilutions of serum ranging from
1:20 to 1:5120 in Blotto containing 0.1% Surfact-Amps 20
(Thermo Fisher Scientific Inc.) were transferred to the arrays
TABLE 1. HA1 antigens (top) and reference rabbit sera
(bottom) used for the development of influenza A antigen
microarray
Name Strain Subtype
H1-99 A/New Caledonia/20/99 H1N1
H1-07 A/Brisbane/59/2007 H1N1
H1-33 A/WS/33 H1N1
H1-09 A/California/6/2009 H1N1
H1-18 A/South Carolina/1/18 H1N1
H2-57 A/Canada/720/05 H2N2
H3-03 A/Wyoming/3/03 H3N2
H3-07 A/Brisbane/10/2007 H3N2
H5-04 A/Vietnam/1194/2004 H5N1
H7-03 A/Chicken/Netherlands/1/03 H7N7
H9-99 A/Guinea fowl/Hong
Kong/WF10/99
H9N2
Rabbit
antiserum Immunogen Strain
anti-H1.99 HA1 A/New Caledonia/20/99
anti-H1.09 HA A/California/06/2009
anti-H2.91 HA1 A/Chicken/NY/29878/91
anti-H3.05 HA1 A/Wisconsin/67/X-161/2005
anti-H3.03 HA1 A/Wyoming/3/03
anti-H5.05 HA1 A/Indonesia/5/05
anti-H7.03 HA1 A/Chicken/Netherlands /1/03
anti-H9.03 HA1 A/Chicken/HongKong/NT366/03
H2.57 A/Canada/720/05
H3.03 A/Wyoming/3/03
H3.07 A/Brisbane/10/2007
H5.04 A/Vietnam/1194/2004
H7.03 A/Chicken/Netherlands/1/03
A/South Caroline/1/18 H1.18
A/WS/33 H1.33
A/Puerto Rico/8/34 H1.34
A/New Caledonia/20/99 H1.99
A/Brisbane/59/2007 H1.07
Quality control slides
Quality control reference serum
Normalisation
Titer calculation
H9.99 A/Guinea fowl/Hong Kong/WF10/99A/California/6/2009 H1.09
50 000
60 000
70 000 H1.18
H1.33
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H1.07
50 000
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FIG. 1. Set-up of antigen microarrays, containing triplicate wells of HA1 peptides of the viruses indicated, and a typical result from testing of
serum from a 9-year-old child sampled before and after the first pandemic wave. Titres are calculated from the inflection point of a dilution ser-
ies, as described in the methods section. X axes denote serum dilutions, and Y axes the median spot fluorescence intensity as measured by Scan-
Array.
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and incubated for 1 h at 37C in a moist chamber. After
washing, goat anti-human IgG (Fc-fragment specific) conju-
gated with Dylight649-fluorescent dye (Jackson Immuno
Research, West Grove, PA, USA) was incubated for 1 h at
37C in a moist chamber. For control experiments with rab-
bit sera, goat anti-rabbit IgG (Fc-fragment specific; Jackson
Immuno Research) was used, conjugated with Cy5-fluorescent
dye. After washing with buffer and then with water to remove
excess of salts, slides were dried. Signals were quantified by a
Scanarray scanner (PerkinElmer) using an adaptive circle (with
a diameter of 80–200 lm).
Quality control
Variation was monitored by testing dilutions of the interna-
tional standard for antibody to pandemic A(H1N1) 2009
influenza virus (IS; http://www.nibsc.ac.uk/documents/ifu/09-
194.pdf). Trays with an H1 titre for the international stan-
dard deviating more than one titre step from the geometric
mean (GMT) of all standards in the particular run were
rejected. Rest variances were normalized. For each tray, all
antibody titres were multiplied by a normalization factor N
that was calculated by N = IStray/l, where IStray is the H1.09
titre of the international standard of the particular tray and
l is the geometric mean of all H1.09 titres of the interna-
tional standards of the particular study. Multiple samples of
one patient were tested on the same tray. Variability of sig-
nals within and between arrays of the same lot, as well as
lot-to-lot consistency of results were determined by measur-
ing variation coefficient (SD/mean signal*100%). Linearity of
the assay was assessed by plotting log-transformed signals
from serially diluted sera for the different antigens.
Data analysis
Microarray slides were scanned using a ScanArray Gx Plus
microarray scanner (PerkinElmer) and median spot fluores-
cence foreground intensity was determined by using Scan-
Array Express (version 4.0) software (PerkinElmer). For
cross-titrations using rabbit sera, the titre indicates the reci-
procal of the highest serum dilution. For human sera, titres
were defined as the interpolated serum concentration that
provokes a response half way on a concentration-response
curve between the minimum and maximum signal. For this,
microarray data were processed with R 2.12.1 statistical
software and titres were estimated with a four-parameter
log-logistic model (reference 23 using R package ‘drc’ URL
http://www.R-project.org/) at the inflection point of a curve
with the fixed maximum readout of 65 536, a minimum of
3000 (arbitrarily chosen to reduce noise due to low signals)
and variable slope. These conditions were chosen because all
saturated signals (measured in low dilutions of high-titre
serum) reached this plateau, and lines from dilution series
were mostly parallel. Titres below the lowest dilution were
set to a value corresponding to half of the reciprocal of the
lowest serum dilution (20) to avoid over-interpretation of
small changes in the background. For calculation of back-
ground reactivity, geometric mean titres were calculated for
each antigen using sera from persons sampled in 2008. Asso-
ciations between the magnitude of a response to HA1 of the
H1 2009 pandemic virus and that of the other antigens were
calculated by linear regression. To calculate the fold increase
in response, minimum titres were set at 40 to avoid over-
interpretation of small changes in the background.
Results
Development of protein microarray (PA)
Arrays were tested using serial dilutions of sera from rabbits
immunized with HA1 proteins from different seasonal influ-
enza viruses. All sera showed high-level reactivity, predomi-
nantly with their homologous antigens and HA1s from viruses
belonging to the same subtype, with the exception of the
serum from a rabbit immunized with influenza A H1N1 2009
(Tables 1 and 2). This rabbit had been immunized with a com-
plete HA protein, in contrast to the other rabbits, and serum
showed broad reactivity across antigens belonging to the same
subtype. From this experiment, we concluded that the antigens
as printed on the arrays were intact. Rabbit sera were used to
test one slide of each batch (25 slides) to monitor the quality.
Quality control
The IS was tested eight times on a single tray by one techni-
cian for determining intra-test variation, and 64 times on dif-
ferent trays during 7 weeks by nine technicians for inter-test
TABLE 2. Results of microarray-based serological testing of
sera from rabbit immunized with HA1 peptides from influ-
enza A viruses belonging to subtypes H1, H2, H3, H5, H7
and H9. Results are expressed as reciprocal of the highest
serum dilution with reactivity at >50% of the maximum sig-
nal
Rabbit
serum H1.18 H1.99 H2.57 H3.03 5.04 H7.03 9.99
anti-H1.99 62 231 20 20 20 20 20
anti-H2.91 20 20 186 20 39 20 20
anti-H3.05 20 20 20 245 20 20 20
anti-H5.05 20 20 20 20 176 20 20
anti-H7.03 20 20 20 20 20 1327 175
anti-H9.03 20 20 20 20 20 20 1603
anti-H1.09a 552 139 20 20 20 20 20
aWhole HA protein.
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variation. The average coefficient of variation (CV) of signals
within each tray was 8% (range 5–12%), except for the H5
antigen, which had a lower CV due to negative signals. Inter-
tray variation was higher, with an average CV of 37% (range
24–59%), except for antigen H5, again because of low
reactivity. Therefore, we decided to normalize calculation of
titres by correction against the IS. This was also possible
because dilution series showed parallel curves (data not
shown).
Kinetics of antibody response in 18 patients infected with
influenza A H1N1 2009
Seventeen cases showed a seroconversion or ‡four-fold
increase in HI or PA antibody titre during follow-up. One
person had no detectable antibodies by either assay. One
HI-negative person had a very clear increase in titre in PA.
The kinetics of response measured by the two methods
were similar, but PA titres developed slightly faster, and five
persons already had detectable antibody by protein micro-
array at first contact, vs. 1 by HI (t = 1) (Fig. 2). Although
this presence of detectable antibodies could be explained by
the timing of sampling (immediately after virological diagno-
sis), an alternative explanation could be lack of specificity.
Therefore, we analysed serum samples from 122 persons
that donated serum in 2008, well before emergence of the
influenza A(H1N1) 2009 pandemic, and in a year with signifi-
cant exposure to influenza viruses of subtype H1.
Baseline serological reactivity in the community prior to
emergence of pandemic influenza A(H1N1) 2009
In the reference group, geometric mean antibody titres
were calculated for each antigen and were highest for anti-
bodies to the recent seasonal influenza viruses H3 2003
and 2007 (75 and 65, respectively), followed by recent sea-
sonal H1 viruses (39 and 42, for H1 1999 and 2007,
respectively) (Fig. 3). Overall, low GMTs were found for
the antibodies to the other antigens. The GMT of antibod-
ies to H1 2009 was 16. An age-related increase in GMT
was observed for all antigens, although different patterns of
age acquisition were observed (Fig. 3). The GMTs of anti-
bodies to historical seasonal influenza viruses H1 1918 and
1933 and pandemic H1 2009 were highest in the oldest age
group only (>60), whereas recent seasonal influenza virus
titres already were higher in the ages over 10. GMTs of
antibodies to the H2 antigen were higher in persons over
40. Only two sera had low level titres to the H5 antigen,
despite high homologous reactivity when rabbit sera or a
standard human reference serum for H5 tested positive
(Table 2 and data not shown).
Serological profiles of individual persons
Clear signatures of infection with a single subtype were
observed in young children with cross-reactivity of antibodies
to HA1 proteins of recent seasonal strains of the same sub-
type, but not to the 1918 or 1933 antigens (Fig. 4). By
10 years of age, 45% of the persons in this group tested
positive to seasonal H3, and slightly less often (28%) to sea-
sonal H1. The maximum proportion of persons with a titre
>40 was higher for H3 than for H1: in the age groups 10–
19, 20–49 and ‡50, these proportions were 65%, 63% and
67% for H1, and 100%, 81% and 78% for H3, respectively.
The age-related increase in serological reactivity most likely
results from repeated exposures leading to boosting of
plasma cells or memory B cells with specificity to influenza A
viruses from previous exposures. This is illustrated by the
response to antigens that were not in circulation during the
lifetime of persons tested, or to which exposure is very unli-
kely (e.g. H7, H9 antigen). The reactivity to these antigens
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FIG. 2. Comparison of kinetics of antibody response to homologous antigen following infection with pandemic influenza virus A(H1N1)2009
measured by protein array and HI test in 16 cases with virologically confirmed influenza A(H1N1) 2009, and two contacts, all without a history
of vaccination. Time points on the X axis denote first, second, third and fourth sampling time point (Materials and methods). (a) Kinetics of
response measured by HI assay per person; (b) kinetics of response measured by protein array per person; (c) proportion of persons with titre
‡40 by time point; (d) proportion of persons with titre ‡40, cumulative.
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increased with age. Almost all adults with detectable antibod-
ies to the 2009 pandemic influenza virus had reactivity to
multiple antigens. Linear regression analysis found a signifi-
cant correlation between the magnitude of responses to
H1.09 and H1.18, and a borderline age-related significant
correlation between magnitude of responses to H1.09 and
H2.56.
Magnitude of homologous and heterologous antibody
responses
Based on the observed GMTs in the reference population,
we chose the arbitrary cut-off of 40 to calculate the fold
increase in antibody titre from the 18 adult patients. The
response to the H1 2009 antigen was greatest, followed by
that to other H1 antigens (Fig. 5). Smaller increases in
average GMT were observed for antigens belonging to other
subtypes, including the non-human H9.
In 21 children who had been sampled repeatedly over the
course of a year spanning the period in which the pandemic
wave occurred in the Netherlands, again the fold increase in
GMT to the homologous antigen was highest. Nine (43%)
children seroconverted. No child had a pre-pandemic titre of
40 or higher. No change in average GMT for other antigens
was observed.
Individual serological profiles following exposure to pan-
demic influenza A(H1N1) 2009
As indicated in the background population (Fig. 3), serum
samples from children showed less heterologous antibodies
in the microarray measurements. In the children’s cohort, a
clear difference was observed in the proportion of children
with a titre against H1 2009, whereas all other reactivities
remained similar. There were no sera that bound to the H5
and H7 antigens, but a few serum samples had low level anti-
bodies to H9 antigen (Fig. 6).
In the group of patients, we compared profiles of patients
grouped according to level of HI response (Fig. 7), showing
that, despite similar HI reactivities, the broader antibody
profile differed greatly between individuals. Two low
responders in HI (maximum titre <80) had a clear response
to infection as measured by protein microarray. Each patient
clearly shows a unique profile of responses with no predict-
able pattern. Some patients showed increases mostly to the
2009 strain, and some response to H1 18 (e.g. Fig. 7f,i).
More often responses to other antigens were observed.
Within H1, these could be primarily limited to recent sea-
sonal antigens (H, K), or include strong responses to old H1
antigens (e.g. patient A). Patient H shows preferential boost-
ing of previous exposures. Some patients had a broader
response, including development of antibodies reactive to
the H3 seasonal influenza antigens (B, D, E). In these cases,
reactivity could be observed to a single antigen or both of
the H3 antigens. (Low level) H2 and H9 reactivities were
observed in some patients, and could be seen independently
(e.g. patient D vs. patient A).
Discussion
We describe the development and initial validation of a first-
generation protein microarray for serological profiling of
humoral immune responses to a range of influenza A HA1
antigens in small volumes of human sera. The results show
that this approach is feasible, correlates well with the results
of HI testing in terms of defining seroconversions, and
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FIG. 3. Geometric mean titres of antibodies to different HA1 anti-
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FIG. 4. Individual reactivity to a range of seasonal, pandemic and non-human influenza viruses in serum samples from persons sampled during
2008 in the Netherlands. Left column indicates year of birth of individuals. ) denotes titre for respective antigen was below 40. + indicates titres
of 40 or more, measured by protein microarray. *Year of birth. Blue bar indicates pandemic years.
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provides an important new tool for antibody profiling for
influenza. The array approach allows simultaneous testing of
small volumes of human sera against up to 100 different anti-
gens in a 1-day procedure. This is a great improvement on
the standard assay repertoire that requires more time, is less
easy to standardize, and may require the use of BSL3 facili-
ties. In addition, the approach chosen allows interpretation
of the reference standard test results against the background
of prior exposures of a person, which may influence the per-
son’s susceptibility to new influenza infections.
In its current form, the array readouts are subtype spe-
cific, as shown by using cross-titration of rabbit hyperim-
mune sera, and when testing sera from children below
10 years of age [24]. With increasing age, reactivity to more
than one subtype was observed, supporting the notion of
broadening of immune responses by repeated exposure to
multiple influenza viruses, and affinity maturation of the anti-
bodies that are produced [25,26]. Although such cross-reac-
tive antibodies are typically directed at more conserved
proteins, a recent paper showed that some epitopes in HA1
are highly conserved within human influenza virus subtypes
[27,28]. Studies mapping the antibody profiles from individual
B-cell clones have shown that these antibodies are a minority
population, but repeated exposure to different influenza virus
strains from infection and vaccination may selectively booster
memory B cells with broader reactivity. The emergence of
such more broadly reactive antibodies has been postulated
as one of the explanations for the relatively mild nature of
infection in healthy adults [28,29]. Furthermore, the same
mechanism also seems to account for the heterosubtypic
antibody responses induced by the addition of certain adju-
vants, like MF59, to influenza vaccines [30]. When testing
antibodies to known seasonal influenza strains alone, the
exposure history of the person remains unknown. In our
dataset, however, we sampled a cross-section of the Dutch
population, and found a low but consistent fraction of older
persons that tested positive for antibodies to avian influenza
virus HAs, in particular H9. Although we can not entirely
rule out that these resulted from natural exposures, the
more likely explanation is that this also results from the
broadening of immune response with repeated exposure to
seasonal influenzas. This is in line with observations by oth-
ers, who found individuals with antibodies to avian influenza
virus HAs when testing vaccines [31–34]. Therefore, the abil-
ity to measure this profile of heterotypic response adds rele-
vant information to studies of population exposure and
vaccine evaluation. An important question that needs to be
addressed is whether such antibodies contribute to protec-
tive immunity. We can not make that conclusion from the
current work. There was good agreement between HI test-
ing and PA when used to identify serological responders, but
less so when plotting correlations between HI and PA indi-
vidual data points. This is most likely explained by the fact
that antibody profiles measured by PA are broader, and
there is considerable variability between persons, as shown
in Fig. 7.
Also, more work is needed to study the evolution of anti-
body responses in older age groups. Here, the higher levels
of antibodies in 60–80-year-old persons are intriguing, but in
the present cohort, we can not rule out that these reflect
vaccine-induced antibody titres.
The observed differences in the background rate of anti-
body reactivity to non-seasonal influenza viruses also shows
that evaluation of exposure to animal influenza viruses by
serological methods needs to be done with caution. The rel-
atively poor HI antibody responses observed for H5, H7 and
H9 infections render conclusions based on this parameter
alone risky, for instance in documenting the absence of infec-
tions in humans for risk assessments [17,35–37]. Conversely,
identifying antibodies to avian influenza viruses in a small
proportion of the population may not reflect true exposures,
even if confirmed by neutralization tests [38–40]. Carefully
designed studies including appropriate controls are needed in
order to draw conclusions about true exposures based on
serology [17,41,42]. Careful analysis of the serological pro-
files as described here can help interpret results from sur-
veys, and this is needed because evidence of human
exposure to avian and swine viruses is mounting [42,43].
An added value of the approach chosen here is the ability
to provide standardized test kits. We have piloted the use of
microarray-based serology in other laboratories, providing
arrays and a protocol plus minimal training of experienced
technicians. Included in the assay design is a standard run
control, for which a reference serum provided by the NIBSC
has been used. By accepting or rejecting test results based
on this positive control performance, one aspect of inter-
assay and inter-laboratory variation can be reduced. We also
found that the variation coefficient was in the same range as
that described by others, but may depend on the type of
slide used for spotting [44]. Future work is directed at vali-
dation of the microarray for veterinary use.
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